Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has transformed the management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL), with FDA approval of tisagenlecleucel (tisa-cel) for pediatric/young adult patients and brexucabtagene autoleucel (brexu-cel) for adults. Efficacy is contingent upon several factors including disease burden. Emerging data suggests that bridging therapy, lymphodepletion and for some patients, consolidation therapy have an important role in the success of treatment. Further, strategies to define and manage immunotoxic side effects including hematotoxicity is critical to safe delivery. Advancements in CAR-T design beyond CD19 represent an ongoing therapeutic evolution. Overall, CAR-T therapy signifies a paradigm shift in B-ALL management, with the potential for improved remission and survival in a historically challenging patient population.
Skip Nav Destination
Review Article|
September 24, 2024
The present and future for CAR-T cell therapy in adult B-cell ALL
Claire Roddie,
UCL, London, United Kingdom
* Corresponding Author; email: [email protected]
Search for other works by this author on:
Alexandros Rampotas
Alexandros Rampotas
University College London, London, United Kingdom
Search for other works by this author on:
Blood blood.2023022922.
Article history
Submitted:
April 5, 2024
Revision Received:
August 21, 2024
Accepted:
August 21, 2024
Citation
Claire Roddie, Alexandros Rampotas; The present and future for CAR-T cell therapy in adult B-cell ALL. Blood 2024; blood.2023022922. doi: https://doi.org/10.1182/blood.2023022922
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal